Figure 6.

Therapeutic administration of RPC1063 preserves body weight and reduces inflammation in a naïve T‐cell adoptive transfer model of colitis. (A) Lymphopenia induced by RPC1063 and KRP203 in C57Bl/6 mice after 5 days of oral dosing, as assessed by measuring circulating CD4⁺ and CD8⁺ T cells, 6 and 24 h after the final dose and compared to vehicle treated animals. (B‐D) Colitis was induced by adoptive transfer of CD4⁺CD45Rb^hi T cells into SCID mice. Daily drug treatment began 21 days post‐transfer, when the first signs of weight loss were observed. (B and D) Body weight was assessed every other day and *P < 0.05 (determined using Student's t‐test). Data are from the same study but displayed on different graphs for clarity. (C) Colon weight to length ratio was determined at the end of the study. n = 10 per group. Error bars represent SEM; *P < 0.05 by one‐way ANOVA.